Promotes cervical mucus production*
Its final contraindications, warnings, and prescribing rules have not been established by an FDA-approved label
Incretin therapies target the class B G protein-coupled receptors GLP-1R and GIPR, expressed mainly in the pancreas and the hypothalamus, while some therapeutical approaches include additional targeting of the related glucagon receptor (GCGR) in the liver
Your healthcare provider can work with you to find the most appropriate treatment approach that balances effective diabetes management with acceptable tolerability
Meanwhile, 10 units at 10 mg/mL delivers 1.0 mg, a dose that belongs in weeks 9 through 12 of the escalation schedule
also listed on the Department of Defense's Prohibited Dietary Supplement Ingredients List Known side effects: In the limited human data available, the most commonly reported adverse effects are mild and transient: injection site redness, swelling, or discomfort, and occasional nausea, fatigue, or headache